This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

FDA Not Solely to Blame for Drug-Approval Delays

It is taking longer for new drugs to get approved by U.S. drug regulators. But while aspersions have been cast at the Food and Drug Administration as the main source of the delays, drugmakers should shoulder some of the blame.

One of the newer theories floating around about why drug regulators seem to take their sweet time is that drug companies are filing inferior applications. If the data submitted in the application are spotty or don't address issues likely to be raised in the review process, the FDA has little choice but to return the application or reject it altogether.

If this is true, drug companies should be spending a lot of time and money making sure their regulatory staffs are up to snuff. Unfortunately, says Merrill Lynch analyst Steven Tighe, the quality of new drug applications sent to the FDA seems to vary widely.

Tighe covers the pharmaceutical industry, so he and his colleagues looked back six years to analyze approval times and rejection rates. The best performers were Merck (MRK - Get Report) and Eli Lilly (LLY - Get Report), which got their drugs approved in an average time of 10.9 months and 11 months, respectively. The average review time for Bristol-Myers Squibb (BMY), Schering-Plough (SGP) and Pharmacia (PHA) ranged from 14.6 months to 15.6 months.

Alas, American Home Products (AHP - Get Report)and Pfizer (PFE - Get Report) brought up the rear of the rankings, with slothlike average review times of 19.8 months and 25.5 months, respectively.

Lost Time Means Lost Money

This is not just an academic exercise. Remember, time is money. By Tighe's reckoning, a one-month delay in a drug's approval equals $41.7 million in lost revenue. So in the past six years, Pfizer has lost a whopping $7.7 billion more than Lilly has due to drug-approval delays, according to the Merrill Lynch analysis.

Now, there are some extenuating circumstances that affect drug-review times, Tighe cautions. For starters, the FDA grants some drugs accelerated-review status, which means decisions are usually reached in 6 months. In 1999, 54% of new drug applications were granted such priority reviews, which pushed down the median review time for the year. But in 2000, only 33% of drugs were granted priority review.

And certain classes of drugs are given more attention at the FDA. AIDS and cancer drugs, for instance, tend to be reviewed faster because of the urgent medical need. At the other end of the spectrum, drugs focused on women's health, such as contraceptives, take the longest to work through the FDA because the need is less, says Tighe, adding that Pfizer develops a relatively large number of women's health drugs.

This variability makes it a bit difficult to judge the future performance of the drug companies, based on their historical records. But for the record, Merck has had one drug, a new antibiotic for bacterial infections, sitting at the FDA for the past 10 months. Lilly has already received tentative approval for its osteoporosis drug, Forteo, less than a year after submission.

Meanwhile, Pfizer has three drugs submitted to the FDA in 1997 and 1998 that are still awaiting decisions.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AHP $16.72 0.00%
LLY $72.65 -1.70%
MRK $57.50 -1.40%
PFE $34.80 -0.57%
AAPL $124.43 -1.54%

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs